Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMZDJ6)

Drug Name

Captopril Drug Info

Synonyms

captopril; 62571-86-2; Capoten; L-Captopril; Lopirin; Captopryl; Cesplon; Captolane; Tensoprel; Dilabar; Acepress; Captoril; Tenosbon; Hypertil; Garranil; Alopresin; Lopril; Acepril; Captoprilum; Aceplus; Acediur; Tensobon; Isopresol;Apopril; Asisten; Captoprilum [INN-Latin]; SQ 14225; SQ-14225; SQ 14,225; SA 333; Captopril

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[2]

Therapeutic Class

Antiviral Agents

Cross-matching ID

PubChem CID: 44093
ChEBI ID: CHEBI:3380
CAS Number: CAS 62571-86-2
TTD Drug ID: DMMZDJ6
ACDINA Drug ID: D00096

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting HUMAN angiotensin-converting enzyme (ACE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ramipril	DMO2TYL	Acute heart failure	BD10-BD13	Phase 2	[3]
Lisinopril	DM54D1G	Hypertension	BA00-BA04	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN angiotensin-converting enzyme (ACE)	TTGFNPD	ACE_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 074532.
2	ClinicalTrials.gov (NCT04345406) Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19. U.S. National Institutes of Health.
3	Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31.
4	Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219.